Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway.
Åslaug Helland, Hege G Russnes, Gro Live Fagereng...
https://pubmed.ncbi.nlm.nih.gov/35568909/Actively Recruiting
Led by Oslo University Hospital · Updated on 2024-02-29
3000
Participants Needed
17
Research Sites
265 weeks
Total Duration
Researchers are evaluating the effectiveness of approved anti-cancer drugs used outside their usual indication for patients with advanced cancer who have specific molecular changes identified through diagnostic testing. This nationwide, phase 2 clinical trial in Norway uses a combined umbrella and basket design with a Simon two-stage model to study various drug and biomarker combinations across different cancer types. Biological samples will be collected at presentation, during treatment, and upon disease progression to better understand drug response and resistance through advanced genetic analyses, including whole genome sequencing. The study involves patients who have advanced cancers no longer benefiting from standard treatments and who have molecular profiles indicating potential benefit from one of the approved drugs in the trial. Participants will receive treatment with drugs such as atezolizumab, alectinib, and others, used beyond their usual indications based on biomarker profiles. Treatment plans are guided by a national molecular tumor board, and fresh tumor biopsies will be collected before treatment to support biomarker studies. New patient cohorts may be opened as needed based on molecular subgroups and drug availability. Participants will be monitored for tumor response, progression-free survival, overall survival, and treatment duration. Data on treatment toxicity will be collected, and all treatment and outcome information, along with molecular screening results, will be reported to the Cancer Registry of Norway. Long-term follow-up will also use national registries to track patient outcomes. Patients who are screened but not enrolled will be followed for 16 weeks to monitor survival and disease progression.
CONDITIONS
Improving Public Cancer Care by Implementing Precision Medicine in Norway
Å
Åslaug Helland, MD PhD
G
Gro LIve Fagereng, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Oslo University Hospital
Lead Sponsor
Haukeland University Hospital
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 4 years or until disease progression, unacceptable toxicity, or withdrawal.
Participants receive treatment with approved drugs outside their standard indication based on their molecular profile and tumor characteristics.
Regular visits as determined by the treating physician during treatment
Duration - Up to 4 years following treatment
Participants are monitored for long-term outcomes including survival, progression, and treatment-related toxicities after treatment ends.
Visits for outcome assessments and registry follow-up
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
20
Have more questions? Get in touch with our team for quick support
Åslaug Helland, Hege G Russnes, Gro Live Fagereng...
https://pubmed.ncbi.nlm.nih.gov/35568909/Oslo University Hospital
Lead Sponsor
Haukeland University Hospital
Collaborating Sponsor